http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Cryoport Celebrates Grand Opening of its Global Logistics Center In New Jersey with Ribbon Cutting Ceremony
-
Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry
-
Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry
-
Cryoport Revenue Grows 59% for Second Quarter 2018; 73% in Biopharma
-
Cryoport Launches CryoStork℠ Insurance to Support IVF Logistics Solutions
-
Cryoport to Report Second Quarter 2018 Financial Results on August 9th, 2018
-
Cryoport Partners with World Courier to Provide Best-In-Class Logistics Platform for Global Cell and Gene Therapy Market
-
Cryoport Delivers Biological Samples for International Space Station; Rocket Launched Today Arrives at International Space Station on Monday
-
Cryoport Set to Join Russell 3000 Index and Russell 2000 Index
-
Cryoport Revenue Grows 48% for First Quarter; 62% in Biopharma
-
Cryoport to Report First Quarter 2018 Financial Results on May 3rd, 2018
-
Cryoport Reports 56% Revenue Growth for Fiscal Year Ended December 31, 2017
-
McKesson Specialty Health and Cryoport Collaborate to Bolster Logistics Services to Support Commercialization of Cell and Gene Therapies
-
Cryoport to Report Fourth Quarter and Fiscal Year 2017 Financial Results on March 6th, 2018
-
Cryoport to Provide DiscGenics with Cutting Edge Cold Chain Logistics Support for its Phase 1/2 Trial
-
Cryoport To Provide TiGenix With Cutting Edge Cold Chain Logistics for Clinical Trial of SEPCELL for the Treatment of Sepsis
-
The Cryoport Biotech Activity Index Decreases 7.1% In Third Quarter of 2017; While the Total Number of Clinical Trials Increases to 934 Worldwide
-
Cryoport Revenue Up 52%; Driven by BioPharma
-
Cryoport to Report Third Quarter 2017 Financial Results on November 2nd, 2017
-
Cryoport Biotech Activity Index, "CoBRA Index", Increases 8.6% In Second Quarter of 2017
-
Cryoport to Provide Nohla Therapeutics with Cutting Edge Cold Chain Logistics to Support Clinical Programs
-
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel
-
Cryoport Launches - Cryoport. Certified. Cool.
-
Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma
-
Cryoport (CYRX) Says Novartis (NVS) Signed Agreement Contracting it Over Initial Three-year Term for Cryogenic Logistics Support of CTL019/CD19 CAR-T Cell Therapy
-
Cryoport to Support Launch of Potential Treatment for Relapsed/Refractory Acute Lymphoblastic Leukemia
-
Cryoport to Report Second Quarter 2017 Financial Results on August 8th, 2017
-
Cryoport Continues to Strengthen Sales Team with Appointments of Colin Coffua as Vice President, Strategic Accounts and John Phillips as Executive Director, Consulting Services
-
Cryoport Biotech Activity Index "CoBRA Index" increases 30.1% in Q1 2017
-
Cryoport to Report First Quarter 2017 Financial Results on May 4th, 2017
-
Cryoport (CYRX) Prices 5.5M Common Stock Offering at $2/Share
-
Cryoport Announces Pricing of Public Offering of Common Stock
-
Cryoport (CYRX) to Offer Common Stock
-
Cryoport Announces Proposed Public Offering of Common Stock
-
Cryoport Revenue Continues to Climb, Reporting 53% Growth for the Quarter Ended December 31, 2016
-
Cryoport to Report Financial Results for the Three and Nine Months Ended December 31, 2016 on March 13th, 2017
-
Cryoport Introduces CryoStork Next Flight Out Cryogenic Logistics Solution for the Reproductive Health Market
-
Cryoport Launches the "CoBRA Index" for a Comprehensive Measure of Activity in the Regenerative Therapy Space
-
Cryoport to Support ProMab Biotechnologies' CAR-T Cell Preclinical Services
-
Cryoport (CYRX) Announces its Validated cCyogenic Logistics Solutions are Supporting Gradalis Clinical Trials
-
Cryoport Supports Gradalis' Vigil® Platform in Clinical Trials for Autologous Immunotherapies for Multiple Cancers
-
Moffitt Cancer Center Taps Cryoport As Exclusive Cryogenics Logistics Provider
-
Cryoport Reports 38% Revenue Growth for the Second Quarter of Fiscal Year 2017
-
Cryoport to Report Second Quarter Fiscal 2017 Financial Results on November 14th
-
Lattice Biologics Inks Strategic Partnerships With OA Centers of America, Resilience, and Cryoport
-
Cryoport Completes Warrant Tender Offer
-
Cryoport Supporting Over 100 Clinical Trials

